Tetraphase plots Q4 launch for first antibiotic after long-awaited OK for eravacycline
It took a few years more than expected, but Tetraphase finally has a product to sell.
Late Monday, the biotech announced that the FDA has approved their lead antibiotic, eravacycline, for complicated intra-abdominal infections (cIAI). The company expects to launch the intravenous drug as Xerava in the US by the end of the year.
The news comes four years after Tetraphase first posted positive Phase III data for the drug in this indication, back when the company thought the antibiotic could also treat complicated urinary tract infections (cUTI). As eravacycline flopped the late-stage study for cUTI, regulators sent the company’s first NDA back demanding a second set of results.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.